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Abstract
EUSOBI and 30 national breast radiology bodies support
mammography for population-based screening, demonstrat-
ed to reduce breast cancer (BC) mortality and treatment
impact. According to the International Agency for
Research on Cancer, the reduction in mortality is 40 % for
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women aged 50–69 years taking up the invitation while the
probability of false-positive needle biopsy is <1 % per round
and overdiagnosis is only 1–10 % for a 20-year screening.
Mortality reduction was also observed for the age groups
40–49 years and 70–74 years, although with “limited evi-
dence”. Thus, we firstly recommend biennial screening
mammography for average-risk women aged 50–69 years;
extension up to 73 or 75 years, biennially, is a second pri-
ority, from 40–45 to 49 years, annually, a third priority.
Screening with thermography or other optical tools as alter-
natives to mammography is discouraged. Preference should
be given to population screening programmes on a territorial
basis, with double reading. Adoption of digital mammogra-
phy (not film-screen or phosphor-plate computer radiogra-
phy) is a priority, which also improves sensitivity in dense
breasts. Radiologists qualified as screening readers should
be involved in programmes. Digital breast tomosynthesis is
also set to become “routine mammography” in the screening
setting in the next future. Dedicated pathways for high-risk
women offering breast MRI according to national or inter-
national guidelines and recommendations are encouraged.
Key points
• EUSOBI and 30 national breast radiology bodies support
screening mammography.
• A first priority is double-reading biennial mammography for
women aged 50–69 years.
• Extension to 73–75 and from 40–45 to 49 years is also
encouraged.
• Digital mammography (not film-screen or computer
radiography) should be used.
• DBT is set to become “routine mammography” in the screen-
ing setting in the next future.
Keywords Breast cancer . Population-based screening .
Digital mammography . Digital breast tomosynthesis (DBT) .
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Introduction
This position paper on screening for breast cancer (BC) has
been proposed by the Executive Board and the Scientific
Committee of the European Society of Breast Imaging
(EUSOBI) and approved by 30 national breast radiology
bodies/sections (Table 1). The aim is to give a clear message
in favour of screening mammography to national/local gov-
ernments, policy makers, referring physicians and the general
population.
Breast cancer as a major health issue and the role
of mammography in early diagnosis
All over the world, BC remains a major issue for public health.
Increasing numbers of new cases and deaths are observed in
both developed and less developed countries, only partially
attributable to the increasing population age. In the 28member
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states of the European Union, there were 361,608 new BC
cases in 2012 and these are estimated to have increased to
373,733 in 2015 (+3.4 %); deaths were 91,585 and 95,357,
respectively (+4.1 %) [1]. No major differences in this trend
can be appreciated across European countries.
Notwithstanding its intrinsic limitations in terms of sensitiv-
ity and specificity, mammography remains the main tool for
population-based mass screening with demonstrated effective-
ness in reducing mortality and allowing for conservative treat-
ment, as already stated by EUSOBI [2]. Tumour stage at diag-
nosis of BC still significantly impacts on overall survival even
in the current era of effective systemic therapy. Thus, early
diagnosis remains crucial. This principle has been recently con-
firmed by an interesting population-based study from the
Netherlands Cancer Registry, which evaluated more than
170,000 BC patients. The proportion of patients receiving
neoadjuvant/adjuvant systemic therapy increased from 53 %
in 1995–2005 to 60 % in 2006–2012. However, in 2006–
2012 the mortality for larger tumours remained greater than
that for smaller tumours, significantly for the comparison of
T1c and T1a stage, and was independent from nodal status [3].
The evidence in favour of screening mammography has
been recently summarized by the International Agency for
Research on Cancer (IARC) [4]. Upon randomized controlled
trials, the reduction in BC mortality due to screening mam-
mography is confirmed for women between 50 and 69 years
of age. Considering 20 cohort studies and 20 case-control
studies, the estimated reduction in BC mortality is 40 % for
women aged 50–69 years who take up the invitation and
23 % when also including those who do not accept the
invitation, as a societal effect of the screening policy.
From cohort studies, a mortality reduction has also been
estimated for women aged 40–49 years and 70–74 years,
though the evidence from published studies was considered
to be “limited”. Available data did not allow the IARC work-
ing group to define an optimal screening interval. However,
we should consider that the majority of European countries
opted for biennial screening in the 50- to 69-year-old cohort.
When 40- to 49-year-old cohort is invited, the yearly interval
is generally adopted in consideration of a potential higher
speed of BC growth and of a lower sensitivity of mammogra-
phy due to the higher breast density.
The average cumulative risk for a false-positive recall in
organized screening programmes has been evaluated by the
IARC working group to be about 20 % for women aged 50–
69 years who have ten screens in 20 years, while the needle
biopsy rate for a false-positive finding is lower than 1 % per
round [4]. In addition, it should be noted that screening mam-
mography allows for both downscaling clinico-pathological
features of invasive BCs and reducing the impact of loco-
regional and adjuvant treatments [5–8].
With regard to overdiagnosis (i.e. the rate of screen-
diagnosed BCs otherwise unnoticed during the patient’s life-
time), the IARC working group accepted the estimate provid-
ed by the Euroscreen working group [9], equal to 6.5 % (range
1–10 %), which was calculated on the basis of the difference
in the cumulative probability of a BC diagnosis among wom-
en receiving or not receiving screening mammography, taking
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into account lead time and underlying increasing incidence. If
these factors are carefully considered, a similar estimate of
overdiagnosis (4–11 %) is also obtained from randomized
controlled trials [4]. Notably, while overdetection (resulting
from a specific action by the breast radiologist evaluating a
finding as suspicious) should be distinguished from overdiag-
nosis (which also implies an essential role of the pathologist)
[10], further efforts should be dedicated to the reduction of the
most important negative consequences of overdiagnosis, i.e.
overtreatment.
Risk of radiation-induced breast cancer
Radiation-induced BCs from mammography were estimated,
based on models including different factors. For the 50- to 69-
year age group, taking into account a latency time of 10 years
and a dose of 2.5 mGy per screening round, the risk of
radiation-induced BC death has been estimated to be 1 per
100,000 screened women. The risk of radiation-induced BC
due to screening mammography is at least 100 times lower
than the probability of avoiding a BC death [4]. Applying a
mortality reduction rate of 43%, biennial screening mammog-
raphy performed in 100,000 women saves 350 lives [11]. For
the 40- to 49-year age group, the problem of radiation effects
must be more carefully considered and depends on the esti-
mated magnitude of radiation- induced BCs. Importantly,
most of radiation-induced BCs will be cured [12].
Screening models
On the basis of the available evidence, the EUSOBI and the
above-listed national breast radiology bodies strongly support
screening mammography of the female population at average
BC risk, typically from 50 to 69 years of age; extension of this
Table 1 List of 30 national breast radiology bodies who signed a Memorandum of Understanding with the European Society of Breast Imaging and
co-authored this paper
Austria WG on Breast Imaging, Austrian Roentgen Society, Österreichische Röntgengesellschaft (ÖRG)
Belgium Senology Section of the Belgian Society of Radiology
Bosnia and Herzegovina Association of Radiology of Bosnia and Herzegovina
Bulgaria Bulgarian Society of Breast Imaging
Croatia Croatian Society of Radiology Working Group of Breast
Czech Republic Association of Czech Breast Radiologists
Denmark Danish Society of Breast Imaging
Estonia Breast Imaging Subgroup of Estonian Society of Radiology
Finland Radiological Society of Finland/Breast Radiologists of Finland
France Société d'Imagerie de la Femme (SIFEM)
Germany AG Mammadiagnostik / Breast Imaging Working Group of the German Roentgen Society
Greece Hellenic Breast Imaging Society
Hungary Section of Breast Diagnostics, Hungarian Society of Radiologists
Iceland The Breast Imaging Group of The Radiological Society of Iceland
Ireland Irish Breast Radiology Group
Israel Israel Breast Imaging Society
Italy Italian College of Breast Radiologists by SIRM (Società Italiana di Radiologia Medica)
Lithuania Lithuanian Radiology Association
Moldova Department of Breast Imaging in the Society of Imagists of the Republic of Moldova
The Netherlands Dutch College of Breast Imaging (DCBI)
Norway Norwegian Society of Breast Imaging
Poland Sekcja Diagnostyki Obrazowej Chorób Piersi; Polskie Towarzystwo Radiologiczne
Portugal Breast Imaging Section of Portuguese Society of Radiology and Nuclear Medicine (SPRMN)
Romania Romanian Society of Breast Imaging
Serbia School of Breast Imaging
Slovakia The Section of Breast Imaging of Slovac Radiologic Society
Spain Spanish Society of Breast Imaging, Sociedad Espaňola de Diagnostico e Interventencionismo de la Mama (SEDIM)
Sweden Swedish Breast Imaging Society
Switzerland Breast screening representative of the Swiss Radiological Society
Turkey Turkish Society of Radiology Breast Imaging Working Group
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up to 73–75 years, biennially, is a second priority. Extension
from 40 or 45–49, with annual screening, can be evaluated as
a third priority, country-by-country. Age selection and screen-
ing interval should be adapted to national demographics and
local priorities. Importantly, these societies strongly discour-
age the use of methods for screening such as thermography or
other optical imaging tools as an alternative to mammography
[13]. Moreover, these societies also discourage the use of ul-
trasound as a primary screening tool in asymptomatic
European women at average risk of BC.
Preference should be given to population-based screen-
ing programmes on a regional/national basis with double
reading rather than spontaneous mammographic screening
with a single reading, given the advantages of the former
in terms of higher specificity and positive predictive value
[14, 15], lower cost, as well as structured quality controls
and central data management. This concept has also been
recently reinforced by the IARC working group in the
above-mentioned paper [4].
In a wider framework, the EUSOBI and the above-listed
national breast radiology bodies are aware of the open debate
in other contexts such as that in the USAwhere the Society of
Breast Imaging and the American College of Radiology sup-
port annual screening mammography from the age of 40 years
by informing women on the advantages of early BC diagnosis
[16]. The recent recommendations of the American Cancer
Society [17] can be a reference for the US context: (1) regular
screening mammography starting at age 45 years (strong rec-
ommendation); (2) annual screening mammography from 45–
54 years of age (qualified recommendation); (3) from 55 years
of age, transition to biennial or continuing annually (qualified
recommendation); (4) opportunity to begin annual screening
from 40–44 years (qualified recommendation); (6) continue
screening mammography as long as women’s overall health is
good and they have a life expectancy of ≥10 years (qualified
recommendation); (7) no suggestion for screening clinical
breast examination at any age (qualified recommendation).
Breast density
The EUSOBI and the above-listed national breast radiology
bodies are aware of the masking effect of increased breast
density, strongly impacting on the sensitivity of screening
mammography, declining from 86–89 % for almost entirely
fatty breasts to only 62–68% for extremely dense breasts [18].
Studies aimed at reducing this negative effect by means of
supplemental screening tools, such as manual or automated
breast ultrasound, are welcome, especially when evaluating
the cost-effectiveness of the additional tools on the large scale
of population-based screening programmes. These societies
also take into consideration the role of breast density as an
independent BC risk factor, although this factor can be over-
rated [19, 20], especially when reported as a communication
to the women. In studies with a control group not limited to
fatty breasts, the relative risk of women with dense breasts
dropped to 2 or less [21, 22]. At any rate, these societies
consider the general adoption of direct digital mammography
to be the first priority to improve the sensitivity in womenwith
increased breast density.
The potential of digital breast tomosynthesis
These societies also consider the increasing evidence in
favour of digital breast tomosynthesis (DBT) as a screen-
ing tool. Three prospective studies showed that DBT
used as an adjunct [23–25] or alternative [26] to two-
dimensional (2D) digital mammography allows for a su-
perior diagnostic performance when compared to the lat-
ter alone. Overall, DBT increases the detection rate from
0.5 to 2.7 per 1,000 screened women and reduces the
recall rate from 0.8 to 3.6 per 100 screened women
[27]. Of note, DBT is now proposed along with synthetic
2D views, practically solving the problem of an in-
creased radiation exposure when DBT is performed as
an adjunct to 2D digital mammography [28–30]. All
these aspects will probably also confer to DBT the status
of future “routine mammography” in the screening set-
ting. However, before introducing DBT in BC screening
outside trials approved by ethical committees, we need
evidence for a statistically significant and clinically rele-
vant reduction in the interval cancer rate. This cautious-
ness is due to the need to avoid an increase in overdiag-
nosis and costs, in the absence of the demonstration of
cost-effectiveness of screening DBT (proof of which may
require very long studies). First results on a reduction
from 0.7 to 0.5 interval cancers per 100 screened women
were very recently reported from a large study in the
USA [31], but further evidence is needed. Moreover,
the probable increase in reading time associated with
the use of DBT in screening [32] and its effects on sus-
tainability of screening programmes should be considered
before routine implementation.
Preference for digital instead of film-screen
mammography
Overall, looking at the course of technological evolution of
mammography in the last decades and at the current trend in
favour of DBT, these societies strongly support the adoption
of direct digital mammography (not phosphor-plate computer
radiography) instead of film-screen mammography in all
countries. In fact, digital mammography implies many sub-
stantial advantages, including lower dose, higher image
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quality, possibility of post-processing, digital archiving, image
transmission and no chemical pollution. We suggest that new
mammographic units should be based on direct digital mam-
mography technology and, when possible, equipped with
DBT in readiness for the next evolution.
Need for certified and subspecialty-trained
radiologists in the context of breast centres
Screening mammograms, with or without DBT, should be read
by radiologists qualified as screening mammography readers.
Proficiency tests at the regional/national/European level are
encouraged in order to guarantee a standardized reading quality
together with minimum screening numbers read per year.
It is essential that there is a continuity of care from screen-
ing mammography to diagnostic breast imaging, to needle
sampling and treatment planning either in the context of a
dedicated breast centre or in a screening centre that has a
well-organized relationship with a diagnostic imaging facility.
Whenever possible, radiologists should operate in the context
of integrated breast units with the help of organized/structured
cooperation among BC specialists.
Quality assurance programmes regarding breast radiology
units/sections are also encouraged in the context of forthcom-
ing new European guidelines for BC screening, diagnosis and
treatment.
Preference for core or vacuum-assisted biopsy
Preference should be given to needle sampling of breast le-
sions using core biopsy or vacuum-assisted biopsy instead of
fine needle aspiration [33], in consideration of the lower false-
negative rate and/or inadequate sampling, unless strict coop-
eration with a cytologist allows for a demonstrable equally
high diagnostic performance. This preference does not apply
for sampling of lymph nodes suspected to be metastatic at
ultrasound of axilla, where fine needle aspiration has been
shown to be effective [34].
Women at increased risk for breast cancer
These societies are in favour of including, whenever possible,
dedicated pathways for high-risk women (lifetime risk equal to
or higher than 20 %), offering magnetic resonance imaging
according to national or international guidelines and recom-
mendations [35–37]. In this regard, policies will be different,
considering the heterogeneity of health systems across coun-
tries. Studies considering risk stratification for different screen-
ing strategies of women at increased BC risk are welcome.
Summary statement
EUSOBI and 30 national breast radiology bodies strongly
support mammography as a population-based mass screening
tool which results in a relevant reduction in BC mortality and
leads to a favourable decrease in both loco-regional and adju-
vant treatments in women attending these programmes.
People and institutions questioning its validity despite a large
body of evidence accumulated in more than three decades put
women’s lives at risk.
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